Mereo BioPharma
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 33
- Market Cap
- $738.4M
- Introduction
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 76
- Registration Number
- NCT04761198
- Locations
- πΊπΈ
Mereo Investigator Site, Fairfax, Virginia, United States
π¬π§Royal Marsden, London, United Kingdom
π¬π§Sarah Cannon UK, London, United Kingdom
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 99
- Registration Number
- NCT03636347
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
π©π°Aarhus Universitetshospital, Aarhus, Denmark
πΈπͺLund University Hospital, Lund, Sweden
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 16
- Registration Number
- NCT03498170
- Locations
- πΊπΈ
inVentiv Health Clinical Research Services LLC, Miami, Florida, United States
The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 16
- Registration Number
- NCT02926326
- Locations
- π¬π§
BioKinetic Europe Ltd, Belfast, United Kingdom
A 6 Month Safety Extension Study of MBGS205
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 143
- Registration Number
- NCT02908074
- Locations
- πΊπΈ
Mereo Research Site, Kenosha, Wisconsin, United States
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 271
- Registration Number
- NCT02730169
- Locations
- π¬π§
Mereo Research Site, Newcastle, United Kingdom
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 282
- Registration Number
- NCT02700919
- Locations
- π·πΊ
Mereo Research Site, Tomsk, Russian Federation
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 91
- Registration Number
- NCT01336959
- Locations
- π¨π³
Novartis Investigative Site, Taipei, Taiwan
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
- Conditions
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 183
- Registration Number
- NCT01332097
- Locations
- π·πΊ
Novartis Investigative Site, St. Petersburg, Russian Federation
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 29
- Registration Number
- NCT01200862
- Locations
- π¨π¦
Novartis Investigative Site, Montreal, Quebec, Canada